Advanced Flower Capital (Nasdaq: AFCG) reported a transitional second-quarter print on August 13, 2026 that was the first clean quarter of the company's new life as a business development company (BDC), and the load-bearing observation is that GAAP net investment income (NII) of $3.5 million ($0.15 per share) understates the value created in the quarter because the NAV per share climbed from $7.90 at March 31, 2026 to $8.25 at June 30, 2026, with $0.17 of that lift coming from a buyback that retired 839,406 shares at a $3.29 weighted average price. The stock closed at $3.16 against an $8.25 NAV, leaving the equity trading at roughly 38% of NAV - a wider discount than at any point since the company completed its REIT-to-BDC conversion on January 1, 2026.
The thesis, in one sentence, is that the AFCG equity is being priced for a high-probability loss cascade from the three nonaccrual cannabis loans (22.7% of portfolio fair value, 35.7% of amortized cost) that the company has not yet fully reserved for in fair value, while the broader portfolio - 17 first-lien senior secured loans, 13.2% weighted average yield, weighted average credit grade 3.1 - is performing and the post-quarter-end activity (a $7.0 million new commitment to CM Counsel, a $3.1 million funded close in July, and the $12.5 million Devi asset sale term sheet announced in July) cuts against the bear case rather than confirming it. The reader's job is to weigh a 62% NAV discount against a nonaccrual overhang that is already partially reserved, against a 13.2% yield portfolio where 77% of fair value carries investment grade 1-3 credit grades, and against a balance sheet that repaid $104.4 million of revolver debt on July 1, 2026 to release $20 million of liquidity for new originations.
The single load-bearing risk is that the 22.7% portfolio fair value held in grade-5 loans (Justice Cannabis at $42.0 million fair value on $77.3 million of amortized cost, Devi at $18.9 million on $37.7 million of cost, DMA at $5.1 million on $11.5 million of cost) suffers another mark-to-market leg lower in a Q3 2026 or Q4 2026 print, pushing NAV per share below $7.90 and forcing the buyback to grind to a halt. The falsifiable clock is the Q3 2026 10-Q, due in early November 2026, which provides the third-party confirmation of the Devi receivership sale (binding term sheet announced in July at $12.5 million gross to a J Brrothers LLC buyer, with AFCG entitled to its pro rata share), the second quarter of post-conversion portfolio activity, and the first quarter of full BDC-grade disclosure under ASC 946 investment-company accounting.